Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed a Form 8-K on February 11, 2026, disclosing preliminary estimated unaudited financial results for the fiscal year ended December 31, 2025. The company is an emerging growth company focused on drug development, currently operating with no revenue and significant operating losses. The filing notes that closing procedures for 2025 are incomplete, and figures are subject to change.
Key Financial Metrics
| Metric | 2025 (Low) | 2025 (High) | 2024 (Actual) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Total Operating Expenses | $10.72M | $11.93M | $7.70M |
| Net Loss | $(10.86M) | $(12.08M) | $(9.14M) |
| Current Assets | $0.50M | $0.50M | $2.21M |
| Current Liabilities | $1.19M | $1.31M | $1.50M |
| Working Capital | $(0.69M) | $(0.81M) | $0.70M |
Balance Sheet Highlights: As of December 31, 2025, the company holds approximately $9.8 million in intangible assets (primarily from the Molecule.ai acquisition) and faces $6.4 million in acquisition-related liabilities (contingent consideration and consideration payable). All notes payable and convertible notes outstanding in 2024 were settled or converted in 2025.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses are estimated to increase by approximately $3.0 million to $4.2 million compared to 2024. This is driven primarily by a $3.6 million increase in General and Administrative (G&A) expenses due to investor relations advertising costs.
- Net Loss: The net loss is projected to widen by approximately $1.7 million to $2.9 million year-over-year.
- Liquidity Position: The company shifted from a positive working capital of $0.7 million in 2024 to a deficit of $0.7 million to $0.8 million in 2025. This deterioration is attributed to a $3.0 million cash payment for the Molecule.ai asset acquisition, costs to wind down clinical trials, and capital preservation efforts.
- Other Income/Expense: Other expenses decreased significantly from $1.5 million in 2024 to an estimated $0.1 million to $0.2 million in 2025, largely due to the settlement of the Alto Convertible Note in the prior year.
Outlook, Risks, and Management Commentary
Management Commentary: The company anticipates a decrease in R&D activities until the direction of preclinical and clinical efforts is determined. The increase in G&A expenses is explicitly linked to advertising for investor relations. The company is actively working to raise additional financing to fund ongoing operations.
Risks and Contingencies:
- Going Concern: The company's ability to continue as a going concern is dependent on successfully raising additional equity or debt financing.
- Unaudited Data: The financial results are preliminary estimates and have not been audited; actual results may vary materially.
- Acquisition Integration: Risks exist regarding the ability to recognize anticipated benefits from the Molecule.ai purchase.
- Dilution: Future issuance of equity or debt securities may dilute share capital.
Investor Verification Checklist
- Verify the final audited financial statements for 2025 to confirm the preliminary loss and expense ranges.
- Assess the status and terms of the $6.4 million in acquisition-related liabilities (contingent consideration and consideration payable).
- Monitor progress on raising additional financing to address the working capital deficit and fund operations.
- Review the strategic direction of R&D efforts and the timeline for any new clinical or preclinical trials.
- Confirm the impact of the $3.6 million investor relations advertising spend on future capital raising efforts.